NAD synthetase inhibitors and uses thereof

Details NAD synthetase inhibitors and uses thereof NAD synthetase inhibitors and uses thereof

2005-03-01

2005-03-01

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S521000, C514S522000, C514S615000, C558S343000, C558S415000, C560S008000, C560S103000, C564S123000, C564S282000

Reexamination Certificate

active

06861448

ABSTRACT:
Disclosed are compounds that inhibit the microbial NAD synthetase enzyme. For example, disclosed are compounds of the formula Ar1—X—Ar2—Y—L—Z—Q, wherein Q is Q1Ar3or Ar3Q1; Ar1, Ar2, and Ar3are independently aryl or heteroaryl, optionally substituted with one or more substituents; X, Y, and Z are independently selected from the group consisting of a covalent bond or groups containing one or more of C, H, N, O, S atoms; L is a linker and Q1is an alkylenyl, alkylenyl carbonyloxy alkyl, or alkylenyl carbonylamino alkyl group, optionally having a substituent; a covalent bond; a group containing amidine or guanidine function wherein the amidine or guanidine may be optionally N-substituted with an alkyl; or a zwitterion; or a pharmaceutically acceptable salt thereof. Also disclosed are methods which involve the use of the compounds of the present invention, for example, in treating or preventing a microbial infection in a mammal or plant, killing a prokaryote or decreasing prokaryotic growth, disinfecting a material or environment contaminated by a microbe, increasing food animal production, controlling harm to plants by a pest or insect, and combating agroterrorism. Examples of microbes affected by the compounds of the present invention are bacteria and fungi.

REFERENCES:
patent: 4275068 (1981-06-01), Thiele et al.
patent: 4289777 (1981-09-01), Albrecht et al.
patent: 4767712 (1988-08-01), Motal et al.
patent: 4797358 (1989-01-01), Misaki et al.
patent: 4859692 (1989-08-01), Bernstein et al.
patent: 4921786 (1990-05-01), Takahashi et al.
patent: 5013743 (1991-05-01), Iwahi et al.
patent: 5093342 (1992-03-01), Tomoi et al.
patent: 5206146 (1993-04-01), Misaki et al.
patent: 5468768 (1995-11-01), Cipollina et al.
patent: 5521197 (1996-05-01), Audia
patent: 5583149 (1996-12-01), Cipollina et al.
patent: 5589349 (1996-12-01), Shinzaki et al.
patent: 5622953 (1997-04-01), Janssen et al.
patent: 5639752 (1997-06-01), Maco
patent: 5659040 (1997-08-01), Blatcher et al.
patent: 5708008 (1998-01-01), Audia et al.
patent: 5744488 (1998-04-01), Cross et al.
patent: 5786473 (1998-07-01), Blatcher et al.
patent: 5834493 (1998-11-01), Gil Quintero et al.
patent: 5849764 (1998-12-01), Goulet et al.
patent: 5932743 (1999-08-01), Collini et al.
patent: 5936098 (1999-08-01), Yasuda et al.
patent: 5962474 (1999-10-01), Audia et al.
patent: 5965582 (1999-10-01), Lebaut et al.
patent: 5977154 (1999-11-01), Bell et al.
patent: 5981525 (1999-11-01), Farina et al.
patent: 5981550 (1999-11-01), Goulet et al.
patent: 5981776 (1999-11-01), Diaz et al.
patent: 5990150 (1999-11-01), Matsui et al.
patent: 5998438 (1999-12-01), Slassi et al.
patent: 6022880 (2000-02-01), Effland et al.
patent: 6037123 (2000-03-01), Benton et al.
patent: 6046136 (2000-04-01), James et al.
patent: 6174873 (2001-01-01), Wrenn, Jr.
patent: 6185541 (2001-02-01), Benton et al.
patent: 6228588 (2001-05-01), Benton et al.
patent: 6339073 (2002-01-01), Pero
patent: 0 090 405 (1983-10-01), None
patent: 0 196 530 (1985-03-01), None
patent: 0 196 530 (1986-10-01), None
patent: A-0268956 (1988-01-01), None
patent: 0 585722 (1994-03-01), None
patent: 646569 (1995-04-01), None
patent: WO 99 36422 (1999-07-01), None
patent: WO 00 10996 (2000-03-01), None
CAPLUS DN 123:285534, also cited as EP 646569.*
PubMed Abstract 11959549, also cited as Antimicrob. Agents Chemother. 46/5, 1226-30(2002).*
PubMed Abstract 12380742, also cited as J. Food Prot. 65/10, 1580-5(2002).*
PubMed Abstract 14612543, also cited ac Cancer Res.,63/21,7436-42(2003).*
PubMed 10681987,also cited as Ann.NY Acad. Sci. 894, 168-80(1999).*
PubMed Abstract 11876121, also cited as Indian J. Pediatr. 69/1,49-56(2002).*
Shridhar et al, J. Pharm. Sci.,65/7,1074-78(1976).*
Brouillette et al., “Synthesis of Inhibitors of Prokaryotic NAD Synthase” American Chemical Society. Abstracts of paper. At the National Meeting, American Chemical Society, Washington, DC, US, vol. 218, No. Part 1, Aug. 22, 1999, pp. 295-MEDI, XP000981304 ISSN: 0065-7727 the whole document.
Brouillette et al., “Synthesis of Inhibitors of Prokaryotic NAD Synthetase”, Abstract ™295, Divisional of Medicinal Chemistry, 218thNational American Chemical Society Meeting, New Orleans, LA, Aug. 22-26, 1999 (Abstract only).
Brouillette et al., Synthesis of NAD Synthetase Inhibitors as Potential Antibacterial Agents, Abstract ™298, Division of Medicinal Chemical, 218thNational American Chemical Society Meeting, New Orleans, LA, Aug. 22-26, 1999 (Abstract only).
Cristofoli et al., “The Synthesis of Tethered Heterocyclic Dimers as Inhibitors of NAD Synthetase”, Gordon Research Conference on Heterocyclic Chemistry, New Port, Rhode Island, Jun. 28-Jul. 3, 1998 (“Title only”).
Cristofoli et al., “The Synthesis of Tethered Heterocyclic Dimers as Inhibitors of NAD Synthetase”, Poster presentation, Gordon Research Conference on Heterocyclic Compounds, 1998, Newport, RI (Abstract only).
Fostel et al., “Comparison of responses of DNA topoisomerase I fromCandida albicansand human cells to four new agents which stimulate topoisomerase-dependent DNA nicking”, FEMS Microbiology Letters vol. 138, 1996, pp. 105-111.
Fostel et al., “Identification of the Aminocatechol A-3253 as an in Vitro Poison of DNA Topoisomerase I fromCandida albicans”, Antimicrobial Agents and Chemotherapy, vol. 39, No. 3, Mar. 1995, pp. 586-592.
Garcia et al., “Combinatorial Synthesis of NAD Synthetase Inhibitors”, Abstract ™297, division of Medicinal Chemistry, 218thNational American Chemical Society Meeting, New Orleans, Louisiana, Aug. 22-26, 1999 (“Title only”).
Garcia et al., “Synthesis of Potential NAD Synthetase Inhibitors as Antibacterial Agents”, Division of Medicinal Chemistry, American Chemical Society National Meeting, Boston, Massachusetts, Aug. 23-27, 1998 (“Title only”).
Garcia et al., “Synthesis of Potential NAD Synthetase Inhibitors as Antibacterial Agents” American Chemical Society (Abstracts). National Meeting, American Chemical Society, Washington, DC, US, vol. 216, No. Part 2, Aug. 23, 1998, pp. 248-MEDI, XP000979956 ISSN:0065-7727.
Groll et al., “Potential new antifungal agents”, Current Opinion in Infectious Diseases, vol. 10, 1997, pp. 449-458.
Kauffman et al., “Antifungal Agents in the 1990s”, Drugs, 53(4), Apr. 1997, pp. 539-549.
Merck Index 1954, p. 1030, compound No. 6434: Nicotine.
Monk et al. “Fungal Plasma Membrane Proton Pumps as Promising New Antifungal Targets”, Critical Reviews in Microbiology, 20(3), 1994, pp. 209-223.
Monk et al., Targeting the fungal plasma membrane proton pump:, Acta Biochimica Polonica, vol. 42, No. 4, 1995, pp. 481-496.
Nafsika H. Georgopapadakou, “Antifungals: mechanism of action and resistance, established and novel drugs”, Current Oponion in Microbiology, vol. 1., 1998, pp. 547-557.
Richardson, “Fluconazole, An Orally Active Antifungal Agent”, Medicinal Chemistry, 2ndEdition, Academic Press, San Diego, CA 1993.
Rizzi et al., “A novel deamido-NAD+-binding site revealed by the trapped NAD-adenylate intermediate in the NAD+ synthetase structure”, Structure, vol. 6, No. 9, 1998, pp. 1129-1140.
Rizzi et al., “Crystal structure of NC3-dependent NAD+ synthetase fromBacillus subtillis”, The EMBO Journal, vol. 15, No. 19, 1996, pp. 5125-5134.
Schmitt et al., “The Synthesis of Tethered Heterocyclic Dimers as Inhibitors of NAD Synthetase”, Division of Medicinal Chemistry, American Chemical Society National Meeting, Boston, Massachusetts, Aug. 23-27, 1998 (“Title only”).
Schmitt et al., “The Synthesis of Tethered Heterocyclic Dimers as Inhibitors of NAD Synthetase”, Abstracts of Papers of the American Chemical Society, vol. 216, part 2, pp. 247-MEDI, Aug. 23, 1998.
Shibata et al.: “Effect of dietary orotic acid on the levels of liver and blood NAD in r

Affiliated with

Also associated with

Rating

NAD synthetase inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NAD synthetase inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NAD synthetase inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3404155